Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

BACKGROUND: Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25% of cholangiocarcinomas, especially intrahepatic cholangiocarcinoma. Ivosidenib is an oral, targeted inhibitor of mutant IDH1 (mIDH1) approved in the USA for the treatment of mIDH1 acute myeloid leukaemia in newly diagnosed patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Gastroenterol Hepatol
Main Authors: Lowery, Maeve A, Burris, Howard A, Janku, Filip, Shroff, Rachna T, Cleary, James M, Azad, Nilofer S, Goyal, Lipika, Maher, Elizabeth A, Gore, Lia, Hollebecque, Antoine, Beeram, Muralidhar, Trent, Jonathan C, Jiang, Liewen, Fan, Bin, Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Gliser, Camelia, Agresta, Samuel V, Pandya, Shuchi S, Zhu, Andrew X, Abou-Alfa, Ghassan K
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934945/
https://ncbi.nlm.nih.gov/pubmed/31300360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2468-1253(19)30189-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados